A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorEli Lilly and Company
About this trial
The main purpose of this study is to evaluate safety and efficacy, and measure how much LY4584180 gets into the bloodstream and how long it takes the body to eliminate it in patients with previously treated blood cancers. For each participant, the study could last about 9 months or possibly longer including screening.
Eligibility criteria
Qualifiers
Diffuse large B-cell lymphoma - not otherwise specified
High-grade B-cell lymphoma
Diffuse large B-cell lymphoma - transformed from indolent lymphomas
Follicular large B-cell lymphoma
Disqualifiers
Has an active second cancer
Has known central nervous system (CNS) involvement by systemic lymphoma. Patients with previous treatment for CNS involvement who are neurologically stable and without evidence of active CNS disease may be eligible and enrolled if a compelling clinical rationale is provided by the Investigator and with documented Sponsor approval.
Has known Cytomegalovirus infection. Participants with negative status are eligible
Has known hepatitis B or C infection or uncontrolled HIV
Trial design
Treatments tested in this trial
- LY4584180
- Rituximab
Treatment groups
460 Participants
are divided into 4 treatment groupsLocations
46France
CHU de Nantes - Hotel-Dieu44093, Nantes France
Institut Curie75005, Paris France
CHU Bordeaux - Hopital Haut-Leveque - Centre Francois Magendie33604, Pessac France
HCL Centre Hospitalier Lyon Sud69495, Pierre-Bénite France
Sponsors and collaborators
Eli Lilly and Company
Lead sponsor
Source ClinicalTrials.gov